Omalizumab

Pronounced

"oh-mal-IZ-oo-mab"

Common brand names:

Xolair

Uses

Omalizumab is used to control and prevent symptoms (such as wheezing and shortness of breath) caused by asthma that is due to year-round allergens. Controlling symptoms of asthma helps you maintain your normal activities and cuts down on time lost from work or school. Omalizumab may also be used to treat certain growths in the nose (chronic rhinosinusitis with nasal polyps) or to treat hives from an unknown cause (chronic idiopathic urticaria-CIU).

This medication must be used regularly to be effective. It does not work right away and should not be used to relieve sudden asthma attacks. If an asthma attack occurs, use your quick-relief inhaler (such as albuterol, salbutamol) as prescribed.

How to Use This Medication

Read the Medication Guide provided by your pharmacist before you start using omalizumab and each time you get a refill. If you are using this medication at home, read and follow the Instructions for Use leaflet. If you have any questions, ask your doctor or pharmacist.

This medication is injected under the skin as directed by your doctor, usually every 2 or 4 weeks for the treatment of asthma or nasal polyps, and every 4 weeks for the treatment of CIU. The first dose is given by a health care professional and you will be monitored in case you have a severe allergic reaction. Later doses may be given by a health care professional or at home.

If you are using this medication at home, learn all preparation and usage instructions from your health care professional. Before using, check this product visually for particles or discoloration. If either is present, do not use the liquid. Learn how to store and discard medical supplies safely.

To increase comfort and make it easier to inject, take the carton(s) out of the refrigerator and let the medication warm to room temperature for at least 30 to 45 minutes before use. Do not warm up this medication in any other way such as heating in the microwave or placing in hot water.

The dosage for the treatment of asthma/nasal polyps is based on your weight and lab test results before you start treatment. Tell your doctor if you have any big changes in weight during treatment. Your dose may need to be adjusted. The dosage for the treatment of CIU is based on your medical condition and response to treatment.

Use this medication regularly to get the most benefit from it. To help you remember, mark your calendar to keep track of when to get the next dose.

Get medical help right away if your asthma symptoms worsen or if you are using your quick-relief inhaler more than usual or more often than prescribed.

Copyright © 2024 TraceGains, Inc. All rights reserved.

RxAnswers™ is a copyrighted combined product from TraceGains and First DataBank, Inc.

Drug information is selected from data included with permission and copyrighted by First DataBank, Inc. This is a summary and does not contain all possible information about this product. For complete information about this product or your specific health needs, ask your healthcare professional. Always seek the advice of your healthcare professional if you have any questions about this product or your medical condition. This information is not intended as individual medical advice and does not substitute for the knowledge and judgment of your healthcare professional. This information does not contain any assurances that this product is safe, effective or appropriate for you.

This information is intended only for residents of the United States. Products sold under the same brand names in other countries may contain different ingredients.

Learn more about First DataBank

There are some limitations on the information provided in “Nutrient Interactions.” Do NOT rely solely on the information in this article. Please read the disclaimer.

Learn more about TraceGains, the company.

TraceGains and/or its suppliers make no warranties or representations as to the accuracy or completeness of this content herein or that of any organization referred or linked to within this content and will not be liable for any damages arising out of your access to or use of any information found herein or that of any organization referred to within this content.

Information expires December 2024.